Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURANDOT II long-term safety extension of PF-00547659 in ulcerative colitis
NL-OMON44981Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ontamalimab in autoimmune colitis, sponsored by Takeda. Primary endpoint: Frequency of on-treatment adverse events. Started Jan 2014; status: active, not recruiting.
02
Drugs
ontamalimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON44981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44981.